characterized “tumor-matching” T cells in the peripheral blood (i.e., T cells in the blood expressing tumor-specific TCRs) as cells that expressed a more effector phenotype with a decreased expression of genes GYPC, CCR7, LTB, and FLT3LG (190). This evidence concerns the gene GYPC and neoplasm.